Preventing primary liver cancer: the HBV vaccination project in the Gambia (West Africa)

Ruggero Montesano

From First Lorenzo Tomatis Conference on Environment and Cancer
Turin, Italy. 4-5 June 2009

Abstract
The Gambia Hepatitis Intervention Study (GHIS) consisted in the progressive introduction of HBV plasma-derived vaccine in different zones of this African country during the period 1986-1990. The study was launched and coordinated by IARC and is one of the most effective examples of an intervention project that both substantially contributed to our knowledge and to the health of local populations. Similar intervention studies have been carried out in South-East Asia. The studies indicate that the natural history of HBV infection differs in different populations, having a direct relevance for the implementation of HBV vaccination programmes in various parts of the world.

Article
Recent estimations provided by GloboCa 2008 [1] indicate that in 2008 12.7 million new cancer cases and 7.6 million cancer deaths occurred in the world and that most of these cancers are present in developing countries either in terms of incidence (56%) or mortality (63%). It is also expected that by 2030 some 21.4 million new cancer cases will be diagnosed and over 13.2 million cancer deaths will occur annually. It is estimated that liver cancer (mostly hepatocellular carcinoma [HCC]) is responsible for more than 600,000 cancer deaths worldwide and represents the third most frequent cause of cancer deaths [2,3]. The major causes of hepatocellular carcinoma have been known since several decades and in the developing countries these are HBV, HCV infections and exposure to aflatoxins through the diet [4-6]. Since the early 1980s an efficient and safe vaccine against HBV infection has been available and various intervention studies, namely in Quidong province, China [7], Taiwan [see 8], and The Gambia [9], have been initiated to assess the efficacy of HBV vaccination at infancy in the prevention of HCC.

All the children vaccinated within the Gambia Hepatitis Intervention Study (GHIS) were registered, resulting in two cohorts of approximately 60,000 children, one of which received only the routine EPI vaccination and the other the HBV vaccine in addition. To determine the response to HBV vaccine and the persistence of vaccine-induced immunity, some 1000 children were recruited consecutively and these have been followed annually to assess their HBV serological status. A cross-sectional survey was carried out at the ages of 4 and 9 years of a similar number of unvaccinated children to determine the vaccine efficacy against HBV carriage status and infection.

The vaccine efficacy shows an 84% protection against infection and 94% against HBV chronic carriage at 9 years of age (See Table 1). The evaluation of the expected protection against the development of HCC is expected from the year 2017 [10]. Similar intervention studies have been carried out in South-East Asia see [7,11]. It is of interest to note that, in the Chinese population, perinatal transmission from mothers positive for HBV antigen is frequent, whereas in Africa horizontal transmission (sibling-to-sibling) is prevalent. The study in Taiwan shows that the incidence rate of HCC in children of 6-19 years of age was considerably lower in children born after the initiation of the HBV vaccination and that this decrease was not present in children born...
from mothers who were positive for HBsAg and HBeAg [11]. These studies in Africa and South-East Asia indicate that the natural history of HBV infection differs in these populations and they have a direct relevance in the implementation of HBV vaccination strategy.

It has been estimated that, in a surviving birth cohort for the year 2000, routine infant HBV vaccination, with a 90% coverage and the first dose administered at birth, would prevent 84% of global HBV related deaths, i.e. 1.4 million [12].

In The Gambia the high incidence of HCC is also associated with exposure to the carcinogen aflatoxin B1 through the consumption of groundnuts and maize contaminated with the fungi Aspergillus flavus and parasiticum [6]. Comprehensive studies have been carried out in this country to assess the relative contribution and the interaction of the different risk factors, namely HBV infection and aflatoxin B1, in the etiopathogenesis of HCC [13,14]. These case-control studies, using serological markers of exposure to HBV and aflatoxin B1 (as determined by the presence of aflatoxin-albumin adduct and of 249th p53 mutation in sera DNA), clearly show that exposure to aflatoxins affects the entire population and that exposure to both HBV infection and aflatoxins results in a prominent increase risk of developing HCC.

In summary, these studies show that HBV vaccination programmes have been successfully implemented in various parts of the world. In addition, molecular epidemiological studies in The Gambia and in South-East Asia have clearly shown the relevance of other major risk factors, namely aflatoxin exposure [see 15], in the etiopathogenesis of HCC.

Acknowledgements
This article has been published as part of Environmental Health Volume 10 Supplement 1: 2011: Proceedings of the First Lorenzo Tomatis Conference on Environment and Cancer. The full contents of the supplement are available online at http://www.ehjournal.net/supplements/10/S1.

Competing interests
The author declare that has no competing financial or non-financial interest.

Table 1 Hepatitis B vaccination trials

| Location | Year of recruitment/ year of Follow up | Prevalence HBsAg Non-vaccinated/ vaccinated population | Efficacy | Relative Risk of developing HCC Non-vaccinated/ vaccinated population |
|----------|---------------------------------------|-------------------------------------------------------|----------|---------------------------------------------------------------|
| The Gambia* | 1986-1990/ 9 yrs | 10% > 1% | 94% | Expected 2017 |
| China* (Qidong) | 1984-1990/ 11 yrs | 7,1% > 1.66% | 75% | Expected >2015 |
| Taiwan* | 1984 | 9.8% in 1984 > 0.7% in 1999 | 84% | 0.31* |

*HBV vaccination trials programme [16,7].
*Universal vaccination programme [11].
*64 HCC among vaccinees in 37709304 person-years versus 444 HCC in unvaccinated subjects in 78496406 person-years [11].

Published: 5 April 2011

References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer. Lyon, France; 2010.
2. Parkin DM, Sasit F, Chineje M, Stein L, Abratt R, Wabinga H: Part I: Cancer in indigenous Africans – burden, distribution, and trends. Lancet Oncology 2008, 9:683-692.
3. Sasit F, Parkin DM, Chineje M, Stein L, Abratt R, Wabinga H: Part II: Cancer in indigenous Africans – causes and control. Lancet Oncology 2008, 9:786-795.
4. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. In Hepatitis Viruses. Volume 59. Lyon: International Agency for Research on Cancer; 1994:45.
5. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. In Hepatitis Viruses. Volume 59. Lyon: International Agency for Research on Cancer; 1994:165.
6. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. In Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. Volume 82. Lyon: International Agency for Research on Cancer; 2002:171.
7. Sun Z, Ming L, Zhu X, Lu J: Prevention and control of hepatitis B in China. J Med Virol 2002, 67:447-450.
8. Beals RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and HBV: a prospective study of 22,707 men in Taiwan. The Lancet 1981, 2:1129-1133.
9. GHIS: The Gambia Hepatitis Intervention Study, The Gambia Hepatitis Study Group. Cancer Res 1987, 47:5782-5787.
10. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, Montesano R, Plymoth A, Sam O, Van der Sande M, Whittle H, Hainaut P, The Gambia Hepatitis Intervention Study: 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypothesis and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidem Biomarkers Prev 2008, 17:3216-3223.
11. Chang MH, You S-L, Chen C-J, Liu C-J, Lee C-M, Lin S-M, Chu H-C, Wu T-C, Yang S-S, Kuo H-S, Chen D-S, Taiwan Hepatoma Study Group: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. JNCI 2009, 101:1348-1355.
12. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS: A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
13. Kirk GD, Bah E, Montesano R: Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 2006, 27:2070-2082.
14. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, Hainaut P, Montesano R: 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005, 24:5858-5867.
15. Wild CP, Gang YY: Mycotoxins and human diseases: a largely ignored global health issue. Carcinogenesis 2009, 31:71-82.
16. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, Whittle HC. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999, 17:2946-2950.

doi:10.1186/1476-069X-10-S1-S6
Cite this article as: Montesano: Preventing primary liver cancer: the HBV vaccination project in the Gambia (West Africa). Environmental Health 2011 10(Suppl 1):S6.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit